217 related articles for article (PubMed ID: 29980789)
21. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs.
D'Angelo D; Mussnich P; Rosa R; Bianco R; Tortora G; Fusco A
BMC Cancer; 2014 Nov; 14():851. PubMed ID: 25409711
[TBL] [Abstract][Full Text] [Related]
22. Role of high mobility group A1/nuclear factor-kappa B signaling in coronary microembolization-induced myocardial injury.
Su Q; Lv X; Sun Y; Yang H; Ye Z; Li L
Biomed Pharmacother; 2018 Sep; 105():1164-1171. PubMed ID: 30021353
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
24. Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 May; 34(3):990-997. PubMed ID: 33555519
[TBL] [Abstract][Full Text] [Related]
25. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
Mannarino L; Craparotta I; Ballabio S; Frapolli R; Meroni M; Bello E; Panini N; Callari M; Sanfilippo R; Casali PG; Barisella M; Fabbroni C; Marchini S; D'Incalci M
Genomics; 2021 Sep; 113(5):3439-3448. PubMed ID: 34339817
[TBL] [Abstract][Full Text] [Related]
27. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Shamai S; Merimsky O
Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
[TBL] [Abstract][Full Text] [Related]
28. Current management options for liposarcoma and challenges for the future.
Kollár A; Benson C
Expert Rev Anticancer Ther; 2014 Mar; 14(3):297-306. PubMed ID: 24397249
[TBL] [Abstract][Full Text] [Related]
29. A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Wagner MJ; Zhang Y; Cranmer LD; Loggers ET; Black G; McDonnell S; Maxwell S; Johnson R; Moore R; Hermida de Viveiros P; Aicher L; Smythe KS; He Q; Jones RL; Pollack SM
Clin Cancer Res; 2022 Jun; 28(11):2306-2312. PubMed ID: 35349638
[TBL] [Abstract][Full Text] [Related]
30. E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers.
Fenner F; Goody D; Protzel C; Erbersdobler A; Richter C; Hartz JM; Naumann CM; Kalthoff H; Herchenröder O; Hakenberg OW; Pützer BM
Eur Urol Focus; 2018 Jul; 4(4):599-607. PubMed ID: 28753861
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
[TBL] [Abstract][Full Text] [Related]
32. TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling.
Zu X; Zhong J; Tan J; Tan L; Yang D; Zhang Q; Ding W; Liu W; Wen G; Liu J; Cao R; Jiang Y
Int J Mol Med; 2015 Mar; 35(3):693-701. PubMed ID: 25572132
[TBL] [Abstract][Full Text] [Related]
33. Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma.
Tamiya H; Sabe H; Yamashita K; Imura Y; Wakamatsu T; Takenaka S
Case Rep Orthop; 2020; 2020():8873185. PubMed ID: 33274094
[TBL] [Abstract][Full Text] [Related]
34. Application of molecular biology to individualize therapy for patients with liposarcoma.
Abbas Manji G; Singer S; Koff A; Schwartz GK
Am Soc Clin Oncol Educ Book; 2015; ():213-8. PubMed ID: 25993159
[TBL] [Abstract][Full Text] [Related]
35. Mode of action of trabectedin in myxoid liposarcomas.
Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
[TBL] [Abstract][Full Text] [Related]
36. The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1.
Massimi I; Guerrieri F; Petroni M; Veschi V; Truffa S; Screpanti I; Frati L; Levrero M; Gulino A; Giannini G
Mol Carcinog; 2013 Jul; 52(7):526-34. PubMed ID: 22389255
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.
Singer S; Socci ND; Ambrosini G; Sambol E; Decarolis P; Wu Y; O'Connor R; Maki R; Viale A; Sander C; Schwartz GK; Antonescu CR
Cancer Res; 2007 Jul; 67(14):6626-36. PubMed ID: 17638873
[TBL] [Abstract][Full Text] [Related]
39. Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Langmans C; Cornillie J; van Cann T; Wozniak A; Hompes D; Sciot R; Debiec-Rychter M; Vandenbempt I; Schöffski P
Oncol Res Treat; 2019; 42(7-8):396-404. PubMed ID: 31170709
[TBL] [Abstract][Full Text] [Related]
40. Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas.
Jones RL; Le Cesne A; Ibrahim T; Garcia Del Muro X; Menge F
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1241-1248. PubMed ID: 30220224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
